

# Echocardiography in Hypertrophic Cardiomyopathy

Linda D. Gillam, MD, MPH, FACC, FASE  
Chair, Department of Cardiovascular Medicine  
Morristown Medical Center/Atlantic Health System

Chanin T Mast Center for Hypertrophic Cardiomyopathy




No disclosures



## Goals

- Understand the echocardiographic features of HCM
- Understand the importance of the mitral valve in HCM
- Learn imaging tips including the use of contrast
- Recognize SAM



## In Hypertrophic Cardiomyopathy, Echocardiography can ....

- Establish the diagnosis/characterize the disease
  - Define patterns of hypertrophy (LV and RV)
  - Assess systolic function
  - Assess diastolic function
  - Quantitate obstruction (at rest and with maneuvers)
  - Assess concomitant mitral valve abnormalities and regurgitation
  - Risk stratify
  - *Differentiate from athlete's heart*
  - *Differentiate from restrictive CM*
- Help guide myectomy and alcohol ablation
- Stress testing in HCM

### American Society of Echocardiography Clinical Recommendations for Multimodality Cardiovascular Imaging of Patients with Hypertrophic Cardiomyopathy

(J Am Soc Echocardiogr 2011;24:473-98.)

**Table 1** Echocardiographic evaluation of patients with HCM

1. Presence of hypertrophy and its distribution; report should include measurements of LV dimensions and wall thickness (septal, posterior, and maximum)
2. LV EF
3. RV hypertrophy and whether RV dynamic obstruction is present
4. LA volume indexed to body surface area
5. LV diastolic function (comments on LV relaxation and filling pressures)
6. Pulmonary artery systolic pressure
7. Dynamic obstruction at rest and with Valsalva maneuver; report should identify the site of obstruction and the gradient
8. Mitral valve and papillary muscle evaluation, including the direction, mechanism, and severity of mitral regurgitation; if needed, TEE should be performed to satisfactorily answer these questions

**ACCF/AHA Guideline**

**2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary**  
**A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines**

*Developed in Collaboration With the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons*

**WRITING COMMITTEE MEMBERS\***



Bernard J. Gersh, MB, ChB, DPhil, FACC, FAHA, Co-Chair\*†; Barry J. Maron, MD, FACC, Co-Chair\*†; Robert O. Bonow, MD, MACC, FAHA‡; Joseph A. Dearani, MD, FACC§||; Michael A. Fifer, MD, FACC, FAHA\*†; Mark S. Link, MD, FACC, FHRS\*¶; Srihari S. Naidu, MD, FACC, FSCAI\*¶; Rick A. Nishimura, MD, FACC, FAHA‡; Steve R. Ommen, MD, FACC, FAHA‡; Harry Rakowski, MD, FACC, FASEI\*¶¶; Christine E. Seidman, MD, FAHA‡; Jeffrey A. Towbin, MD, FACC, FAHA†‡; James E. Udelson, MD, FACC, FASNCS§§§; Clyde W. Yancy, MD, FACC, FAHA||

**ESC GUIDELINES**

**2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy**

**The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)**

Authors/Task Force members: Perry M. Elliott\* (Chairperson) (UK), Aris Anastasakis (Greece), Michael A. Borger (Germany), Martin Borggrefe (Germany), Franco Cecchi (Italy), Philippe Charron (France), Albert Alain Hagege (France), Antoine Lafont (France), Giuseppe Limongelli (Italy), Heiko Mahrholdt (Germany), William J. McKenna (UK), Jens Mogensen (Denmark), Petros Nihoyannopoulos (UK), Stefano Nistri (Italy), Petronella G. Pieper (Netherlands), Burkert Pieske (Austria), Claudio Rapezzi (Italy), Frans H. Rutten (Netherlands), Christoph Tillmanns (Germany), Hugh Watkins (UK).

## Defining “Hypertrophy”

- Wall thickness (any segment) >15 mm (?12 mm women)
- Septal to posterior wall thickness ratio >1.3 in normotensive pts. or 1.5 in hypertensive pts.

## Define patterns of hypertrophy

## Presence of hypertrophy and its distribution

- Classically asymmetric but can be in any pattern and at any location, including the right ventricle
- Although septal predominance is more common, hypertrophy can be isolated to the LV free wall or apex
- RV hypertrophy (may be in any location) is rare
  - >5 mm subcostal window

# Asymmetric Septal Hypertrophy




## Asymmetric septal hypertrophy (with SAM)



# Asymmetric septal hypertrophy



Morristown  
Medical Center




Morristown  
Medical Center

## Multiple wall hypertrophy



Morristown  
Medical Center


## Apical lateral wall hypertrophy




Morristown  
Medical Center



# Apical hypertrophy





# Apical hypertrophy



# Imaging

Use all windows, increase brightness,  
increase grey scale and use contrast





Morristown  
Medical Center

## Reminder


- Not all genotypically positive pts have increased wall thickness
  - Troponin T mutations (mild)
  - Myosin binding protein C (late)
- Wall thickness > 30 mm predictive of SCD

Morristown  
Medical Center

## Assessment of LV systolic function

- LV EF is usually normal or increased BUT DTI S wave and strain may be impaired
  - DTI S wave  $< 4$  cm/sec predictive of HF and death
- Overt LV systolic dysfunction, “dilated or progressive phase of HCM,” “end-stage HCM,” or “burnt-out HCM,” is usually defined as an LV EF  $< 50\%$  and occurs in a minority (2%–5%) of patients
  - Prognosis is markedly worse in the presence of LV systolic dysfunction

## Strain



**Dyssynchrony common (inter- and intra-ventricular)**

Morristown Medical Center

## LV diastolic function

- Diastolic dysfunction has been reported in patients with HCM irrespective of the presence and extent of LV hypertrophy
- Correlations between the mitral inflow and pulmonary venous flow velocities and invasive parameters of LV diastolic function is relatively weak
- E/e' correlation with LV filling pressures is also modest

## LA size

- LA size provides important prognostic information in HCM
- LA enlargement in HCM is multifactorial in origin,
  - mitral regurgitation
  - the presence of diastolic dysfunction
  - possibly atrial myopathy
- LA volume indexed to body surface area should be assessed in accordance with ASE guidelines

## The Nature of the Obstruction

**Ultrasound Localization of Left Ventricular Outflow Obstruction in Hypertrophic Obstructive Cardiomyopathy**

By PRADY M. SHAI, M.D., RAYMOND CHAMBERLAIN, M.D., AND DAVID H. KRASUS, M.D.

**SUMMARY**  
 Simultaneous recordings of selected ultrasonics from the anterior mitral leaflet and left ventricular outflow, the ECG, the phonocardiogram, and a recording of the carotid artery pulse were obtained in six patients with hypertrophic obstructive cardiomyopathy. Absent sharp systolic anterior movement (SAM) of the mitral leaflet was observed. This movement began with the onset of ventricular contraction and reached a peak with the initial peak in the aortic pulse. The leaflet was opposed to the interventricular septum up to 80% of the systolic period. In the latter part of systole the mitral leaflet moved away from the interventricular septum, the aortic pulse showed a second systolic wave. Onset of SAM coincided with onset of the ventricular ejection. Spontaneous variation in amplitude of SAM coincided with alterations in contour of the aortic pulse and in the intensity of the murmur. Administration of amyl nitrite to four patients resulted in disappearance of SAM. In one patient following surgery, the SAM of the mitral leaflet was noted only in the post-atrial bypass. This specific abnormality of mitral leaflet movement represents the localization of dynamic mitral obstruction in hypertrophic obstructive cardiomyopathy.

**Additional Indexing Words:**  
 Hypertrophic obstructive cardiomyopathy (HOCM) Anterior mitral leaflet Systolic anterior movement

**THE** physiologic behavior of left ventricular (LV) outflow in hypertrophic obstructive cardiomyopathy (HOCM) has been studied extensively over the last 10 years.<sup>1-4</sup> However, the anatomic site of obstruction has been elusive. It is generally difficult to appreciate the obstruction locus in the exposed conducting heart.<sup>5</sup> Earlier angiographic demonstration of a probable site of obstruction was questioned by Criley and associates.<sup>6</sup> They introduced the concept of cavity obliteration as the cause of artificial pressure gradients. Based on observations at surgery, Spick<sup>7</sup> proposed that anatomical hypertrophy of the anterior mitral leaflet. This leaflet balloons into the outflow tract and results in obstruction. This view of the mechanism of LV outflow obstruction did not find general support. More recently D'Amico and co-workers<sup>8</sup> have demonstrated angiographically an abnormal anterior movement of the anterior mitral leaflet during systole. These observations were extended by Shimizu and associates<sup>9</sup> who con-





Figure 2

Morristown Medical Center



SAM-septal contact < 10% = mild, >30% = severe



Pollick C, Rakowski H, Wigle ED. Circulation 69:43, 1984  
 Morristown Medical Center

## SAM-septal contact

- Associated with
  - notching of the aortic valve (M-mode)
  - Mitral regurgitation

## Dynamic gradient

- Dynamic – increases gradually throughout systole to reach its peak in mid to late systole






## Dynamic gradient



- Place of obstruction identified with PW/color
- Peak (measured with CW) influences treatment
  - >30 mmHg at rest a risk for SCD and HF

## Provocative Maneuvers

- Valsalva
- Positional change
- Amyl nitrate
- Exercise




## SAM= Malcoaptation



Grigg LE, Wigle ED, Rakowski H. J Am Coll Cardiol 20:42, 1992

## HCM and MR



Why?  
Morristown  
Medical Center





Progress in Cardiovascular Diseases 54 (2012) 517–522  
[www.onlinepcd.com](http://www.onlinepcd.com)


### Diversity of Mitral Valve Abnormalities in Obstructive Hypertrophic Cardiomyopathy

João L. Cavalcante<sup>a</sup>, Joaquim S. Barboza<sup>b</sup>, Harry M. Lever<sup>a,\*</sup>

<sup>a</sup>Cleveland Clinic Foundation, Department of Cardiovascular Medicine, Section of Cardiac Imaging, Cleveland, OH  
<sup>b</sup>Henry Ford Hospital, Internal Medicine Department, Detroit, MI



Morristown  
Medical Center







## Mitral regurgitation

- Not all mitral regurgitation associated with HCM is related to SAM
- Patients with HCM can have intrinsic valvular abnormalities, such as
  - “degenerative” changes, mitral valve prolapse, leaflet thickening secondary to injury from repetitive septal contact or turbulent regurgitation jet, etc
- The presence of a central or an anteriorly directed jet should prompt careful evaluation of the mitral valve to identify intrinsic valvular abnormalities



## Surgical Treatment

- Should take into consideration mitral valve anatomy and function



$174/1152 = 15\%$

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY  
© 2016 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION  
PUBLISHED BY ELSEVIER

VOL. 68, NO. 14, 2016  
ISSN 0735-1097/\$36.00  
<http://dx.doi.org/10.1016/j.jacc.2016.07.735>

ORIGINAL INVESTIGATIONS

### Mitral Regurgitation in Patients With Hypertrophic Obstructive Cardiomyopathy

Implications for Concomitant Valve Procedures


Joon Hwa Hong, MD, PhD,<sup>a</sup> Hartzell V. Schaff, MD,<sup>b</sup> Rick A. Nishimura, MD,<sup>b</sup> Martin D. Abel, MD,<sup>c</sup>  
Joseph A. Dearani, MD,<sup>a</sup> Zhuo Li, MS,<sup>a</sup> Steve R. Ommen, MD<sup>b</sup>



## Take home points


- Mitral valve anatomic abnormalities are an intrinsic but often underappreciated component of HCM
- Mitral regurgitation and LVOT obstruction go hand in hand
- Mitral regurgitation may confound the noninvasive assessment of LVOT gradients
- MR due to HCM has a typical appearance
- The mitral valve should be carefully evaluated in surgical decision making for HCM

## Apical aneurysms






## Apical aneurysm??




Morristown  
Medical Center


## Crypts




Morristown  
Medical Center



# Coronary Cameral Fistula





## Non compaction - HCM





## Imaging Tips


## Common Errors

- Confusing LVOT gradient with MR
- Failure to “see the SAM”
- Failure to see the true apex
- Failure to address the mitral valve apparatus

## Common Errors

- Confusing LVOT gradient with MR
- Failure to “see the SAM”
- Failure to see the true apex
- Failure to address the mitral valve apparatus
- *Failure to see crypts*


## Scan from LVOT to MR




## Math check

- Use peak mitral velocity to estimate LVSP
- Estimated LVSP – SBP  $\approx$  peak LVOT gradient

Estimated LVSP  $\approx 228 + 10 = 238$



LVSP-gradient = SBP  
238-135 = 103!





Morristown  
Medical Center



## Common Errors


- Confusing LVOT gradient with MR
- Failure to “see the SAM”
- Failure to see the true apex
- Failure to address the mitral valve apparatus

Morristown  
Medical Center










## Common Errors



- Confusing LVOT gradient with MR
- Failure to “see the SAM”
- Failure to see the true apex
- Failure to address the mitral valve apparatus

# Easy to Miss

Morristown  
Medical Center





Morristown  
Morristown  
Morristown





## Contrast can help


## Common Errors

- Confusing LVOT gradient with MR
- Failure to “see the SAM”
- Failure to see the true apex
- Failure to address the mitral valve apparatus









Contrast can help

## Echocardiography is essential in HCM

- Defining structure and function
- Many features under appreciated and may be under-recognized
- Be on the look out for SAM and optimize images

Thank you!



Morristown Medical Center: Led by Drs. Martin and Barry Maron, Ethan Rowin